MedTrace Logo

Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects

NCT05523401 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-03-05

No results posted yet for this study

Summary

4-bromo-2,5-dimethoxyphenethylamine (2C-B) is a psychoactive substance with reportedly similar acute effects to both the prototypical empathogen 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and the classic psychedelic substance psilocybin (contained in "magic, hallucinogenic mushrooms"). Pharmacologically, MDMA mainly releases serotonin (5-HT) via the serotonin transporter (SERT) and psilocybin mainly acts as direct agonist at 5-HT2A receptors. 2C-B interacts with both the 5-HT2A receptor and SERT which is in line with its reported mixed effects profile. However, scientific studies are lacking. There is an increased interest in psychiatric research on the therapeutic properties of MDMA and psilocybin and also on mixed empathogenic-psychedelic substances.

Conditions

  • Healthy

Interventions

DRUG

4-bromo-2,5-dimethoxyphenethylamine (10 mg)

A low dose of 10 mg 2C-B will be administered.

DRUG

4-bromo-2,5-dimethoxyphenethylamine (20 mg)

A medium dose of 20 mg 2C-B will be administered.

DRUG

4-bromo-2,5-dimethoxyphenethylamine (30 mg)

A high dose of 30 mg 2C-B will be administered.

DRUG

3,4-methylenedioxymethamphetamine

A moderate dose of 125 mg MDMA will be administered.

DRUG

Psilocybin

A moderate dose of 25 mg psilocybin will be administered.

OTHER

Placebo

Placebo (Mannitol)

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Matthias E Liechti, MD · University Hospital, Basel, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-16
Primary Completion
2024-10-20
Completion
2024-11-05

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05523401 on ClinicalTrials.gov